Psychedelic Research

The U.S. Department of Health and Human Services and the Department of Veterans Affairs have announced a landmark partnership to accelerate research and implementation of rapid-acting mental health treatments for veterans, including psychedelic-assisted therapies. Read the official federal announcement below.

Nearly 5 Million U.S. Veterans Have Used Psilocybin Mushrooms, LSD or MDMA; Veterans' Policy Preferences Differ by Psychedelic Substance

Originally published in the Hartford Courant, this op-ed examines Connecticut's Public Act 26-108 and its implications for psychedelic-assisted therapy, evidence-based healthcare innovation, and patient access.

New VA Trial of MDMA Psychedelic for PTSD

Starting July 1, CT medical program using psychedelics opens to the public.

New discoveries are reshaping scientific understanding of psychedelic compounds and their potential role in treating mental health conditions. The Atlantic explores the research driving this rapidly evolving field.

Oregon’s psilocybin services program offers an early case study for states considering how to expand access to psychedelics while maintaining responsible safety protections.

The American Alternative Care Policy Network (AACPN) has announced a national policy agenda focused on expanding access to evidence-based integrative and alternative healthcare. Through its Alternative Care Access Campaign, Psychedelic Research Initiative, and Hemp Beverage Policy Initiative, AACPN seeks to advance healthcare access, scientific research, patient choice, and evidence-based policy for veterans, trauma survivors, first responders, and other underserved populatio

Millions of Americans—including veterans, first responders, seniors, and trauma survivors—face barriers accessing treatments that may improve their quality of life because insurance coverage has not kept pace with scientific research. AACPN's Alternative Care Access Campaign advocates for Medicare, Medicaid, VA, and private insurance policies that incorporate evidence-based alternative and integrative healthcare treatments shown to be safe, effective, and beneficial to patien

AACPN is calling for expanded scientific research into psychedelic-assisted therapies as potential trauma treatment options for survivors of sexual violence. The organization says survivors deserve compassionate, evidence-based care and continued research into emerging mental health therapies including MDMA, psilocybin, and ketamine-assisted treatment.

The American Alternative Care Policy Network (AACPN) this week launched its Psychedelic Research Initiative to support continued scientific research into emerging therapies that may help address some of America's most difficult mental health challenges. At the center of this effort are veterans. For many veterans, the invisible wounds of service can persist long after they return home. Post-traumatic stress, depression, anxiety, traumatic brain injury, substance-use disorders

AACPN applauds Connecticut’s enactment of Public Act 26-108, expanding the state’s psychedelic-assisted therapy pilot program and supporting continued clinical research involving MDMA and psilocybin therapies for veterans, first responders, trauma survivors, and individuals living with treatment-resistant mental health conditions.

AACPN welcomes the U.S. Department of Veterans Affairs’ launch of a clinical trial evaluating MDMA-assisted therapy for veterans living with PTSD and alcohol use disorder. The organization says rigorous scientific research is essential to understanding whether emerging therapies can safely and effectively support veterans and other trauma survivors facing complex behavioral health challenges.

The U.S. Department of Veterans Affairs has launched a new MDMA-assisted therapy clinical trial focused on veterans with PTSD and trauma-related conditions. The initiative reflects growing interest in evidence-based psychedelic-assisted therapies and broader efforts to expand innovative mental health treatment options for veterans and other trauma survivors.

The American Alternative Care Policy Network (AACPN) welcomes the unanimous passage of Louisiana legislation establishing a state-backed psychedelic-assisted therapy research initiative focused on mental health and substance-use disorders. The legislation reflects growing bipartisan recognition that treatment-resistant mental illness, PTSD, addiction, and veteran suicide require continued exploration of evidence-informed therapeutic innovation and expanded clinical research.

The proposal would create a state initiative for clinical studies involving ibogaine and psilocybin

The American Alternative Care Policy Network (AACPN) today announced its launch, establishing a policy-driven platform to accelerate the integration of evidence-based alternative therapies into the U.S. healthcare system—where they can deliver measurable outcomes, expand access, and reduce long-term costs. AACPN enters a fragmented and often unserious policy environment with a clear mandate: impose rigor, elevate standards, and translate validated therapies into actionable le